Infinity Pharmaceuticals Provides Company Update and Second Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises in broad rebound; yields push markets towards weekly declines
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Infinity Pharma (INFI) Tops Q2 EPS by 3c
July 30, 2020 5:24 PM EDTInfinity Pharma (NASDAQ: INFI) reported Q2 EPS of ($0.16), $0.03 better than the analyst estimate of ($0.19).
We have made important clinical progress this quarter including the generation of early, but encouraging signals of clinical activity in the triple negative breast cancer cohort of MARIO-3, said Adelene Perkins, Chief Executive Officer and Chair of Infinity Pharmaceuticals. While these data are preliminary, we are... More
